Skip to main content
Advertising

Originally published January 8, 2014 at 11:38 AM | Page modified January 8, 2014 at 6:13 PM

  • Share:
           
  • Comments (0)
  • Print

Seattle Genetics, AbbVie broaden partnership


The Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

NEW YORK — Seattle Genetics said Wednesday it expanded a cancer treatment collaboration with drugmaker AbbVie.

The Bothell company said it will receive a $25 million upfront payment from AbbVie, and it could get $255 million in license and milestones payment per drug. AbbVie also agreed to pay Seattle Genetics royalties in the single digits on sales of any drugs that are approved.

Shares of Seattle Genetics rose $1.04, or 2.6 percent, to $41.04 Wednesday.

Seattle Genetics and Abbott Laboratories started working together in March 2011 on experimental antibodies designed to fight cancer. The antibodies are designed to selectively deliver anticancer drugs to tumor cells. Abbott made an $8 million upfront payment. In October 2012 the companies agreed to expand their partnership, and Abbott paid Seattle Genetics an additional 25 million.

AbbVie was spun off from Abbott a year ago. It sells branded prescription drugs, including the blockbuster anti-inflammatory drug Humira, which is used to treat rheumatoid arthritis, psoriasis and Crohn’s disease.



News where, when and how you want it

Email Icon

Meet the winemakers

Meet the winemakers

View video interviews, conducted by The Seattle Times wine writer Andy Perdue, profiling five of our state's top winemakers.

Advertising

Advertising


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►